avita's relationship with mesoblast

Australian Avita shareholders are probably better aware than I am that Australian company Mesoblast is generally a competitor in that both provide wound care products. Last week, Mesoblast bought the rights of a product, Prochymal, from another wound care product provider, Osiris, a U.S. firm, symbol, OSIR. For what it may be worth, the product which Mesoblast bought will not impact negatively on potential sales of ReCell. Prochymal is used for entirely other medical problems such as heart disease, Crohn's disease etc. and not for wound care as such. FWIW.